ASX News

First Patients Dosed in Clinical Trial of Novel Lung and Ovarian Cancer Theranostic

Melbourne and Adelaide (Australia) – 21st September 2020. Telix announces first two patients dosed in phase I trial of lung & ovarian cancer theranostic

Telix Pharmaceuticals Limited is pleased to announce that the first two patients have been dosed in a phase I study of the novel lung and ovarian cancer theranostic APOMAB™, at the Royal Adelaide Hospital (‘RAH’). The clinical study which is being conducted by the Central Adelaide Local Health Network (‘CALHN’) is co-funded by Telix and strategic partner, AusHealth®.

The study, which is being led by RAH Cancer Clinical Trials Unit Head Professor Michael Brown is a two-arm trial of an antibody that targets the La/SSB protein (APOMAB™), initially labelled with Zirconium-89 (89Zr-APOMAB) to enable the biological and targeting properties of the agent to be evaluated using positron emission tomography (PET).

The target of APOMAB, the La/SSB protein, is specifically expressed by cancer cells that have been treated with chemotherapy and/or radiation, and the research objective of the study is to evaluate how well APOMAB is able to potentially deliver diagnostic and therapeutic targeted radiation to advanced lung or ovarian cancers.

To read the full ASX release please click here.

More Articles

Corporate Spotlight

First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product in Turkey

Melbourne (Australia) and Istanbul (Turkey) – 22nd October 2020. Telix and Eczacıbaşı-Monrol Nuclear Products Co. are pleased to announce that...

Corporate Spotlight

Telix Pharmaceuticals to Participate at AusBiotech + Invest 2020

12th October 2020 – Corporate Spotlight | Telix Pharmaceuticals will participate in AusBiotech + Invest 2020

Corporate Spotlight

Telix to Present at European Association of Nuclear Medicine 2020 Annual Congress

12th October 2020 – Clinical Spotlight | Telix to Present at European Association of Nuclear Medicine 2020 Virtual Conference

ASX News

Telix Granted FDA Orphan Drug Designation for Glioma Imaging Agent

Melbourne (Australia) – 6th October 2020. Telix Pannounces FDA has granted Orphan Drug Designation (ODD) for O-(2-[18F]fluoroethyl)-L-tyrosine for PET imaging...

ASX News

Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product

Melbourne (Australia) and Indianapolis (U.S.A.) – 24th September 2020. Telix Pharmaceuticals submits NDA to US FDA for TLX591-CDx (Kit for...

ASX News

First Patients Dosed in Clinical Trial of Novel Lung and Ovarian Cancer Theranostic

Melbourne and Adelaide (Australia) – 21st September 2020. Telix announces first two patients dosed in phase I trial of lung...

ASX News

Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging

Melbourne (Australia) and Palo Alto, CA (USA) – 3rd September 2020. Telix announces it has entered into a strategic collaboration...

ASX News

Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging

Herstal and Fleurus (Belgium) – 1st September 2020. Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s...

ASX News

FDA Grants Orphan Drug Designation for TLX102

Melbourne (Australia) – 31st August 2020. Telix announces the FDA has granted ODD for 4-[211At] astato-l-phenylalanine for the treatment of...

ASX News

Half Year Shareholder Update

Melbourne (Australia) – 21st August 2020. Telix Pharmaceuticals Limited Announces Half-year Shareholder Update

ASX News

First patient dosed in renal cancer imaging study in Japan

Melbourne (Australia) – 18th August 2020. Telix announces the first patient has been dosed in a Phase I/II study of...

ASX News

Drug Master File for Glioblastoma Therapy Product Filed with FDA

Melbourne (Australia) and Indianapolis, IN (USA) – 11th August 2020. Telix announces it has submitted a Drug Master File to...

ASX News

Completion of Phase I Enrolment of Japanese Renal Cancer Study

Tokyo (Japan) – 27th October 2020. Telix Pharmaceuticals Japan K.K. is pleased to announce the completion of Phase I enrolment...